Sophiris says it’s ready to get back on track with lead drug after patient death — but questions linger
Sophiris’ shares $SPHS took a beating two months ago when the biotech disclosed that a patient died on the same day of a second administration of their drug topsalysin in a Phase IIb prostate cancer trial.
That death caused the biotech to put a brake on their dosing plans. Now, they’d like to wipe the slate clean of any nagging safety issues.
In a new statement out this morning, the San Diego-based biotech says the researchers involved have concluded that their patient had likely died as a result of “sudden cardiac death probably due to an arrhythmia…The investigator and the company concur that the event is unlikely related to topsalysin or the procedure.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
